查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2004169

口服避孕药市场：按产品类型、配方、剂量、品牌和分销管道分類的全球市场预测，2026-2032年

Oral Contraceptive Pills Market by Product Type, Formulation, Dosage Strength, Brand, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，口服避孕药市场价值将达到 196.6 亿美元，到 2026 年将成长至 210.5 亿美元，到 2032 年将达到 317.7 亿美元，复合年增长率为 7.09%。

主要市场统计数据
基准年 2025 196.6亿美元
预计年份：2026年 210.5亿美元
预测年份 2032 317.7亿美元
复合年增长率 (%) 7.09%

对现代口服避孕药市场进行简要概述，重点关注影响相关人员决策的临床、监管和准入趋势。

口服避孕药仍然是全球生殖健康策略的基石，其在计划生育、临床护理和公共卫生政策中的作用也在不断演变。医疗服务提供者、保险公司和生产商所处的环境受到监管重点变化、远端医疗的扩展以及患者对安全性、便利性和成本透明度的期望不断提高的影响。因此，对于那些必须在临床疗效与供应链和商业性现实之间取得平衡的利害关係人相关人员，了解影响处方行为、依从性和可及性的趋势至关重要。

数位医疗的扩张、监管调整和製剂的演变如何重塑口服避孕药市场的取得途径、处方行为和供应商策略。

口服避孕药市场正经历着变革性的转变，产品研发、处方、分销和使用者认知正在改变。数位医疗的进步加速了远端医疗咨询和线上药局配药的发展，加快了处方笺取得速度，但也带来了合规性和检验的新挑战。同时，一些地区正在推动非处方药（OTC）的普及，而另一些地区则在扩大药剂师的处方权。这些因素正在改变传统的准入把关安全隔离网闸，并促使生产者重新思考包装、标籤和病患支援服务。

本分析探讨了美国近期采取的关税措施如何促使整个口服避孕药生态系统进行供应链重组、来源多元化和筹资策略调整。

美国近期实施的贸易政策措施对口服避孕药供应链的各个环节都产生了累积影响。进口关税的提高和对上游供应商监管力度的加强，正在改变活性成分和生产配方成本的计算方式，促使製造商重新评估筹资策略、製造地和库存政策。因此，企业越来越多地探索近岸外包、双重采购和长期供应商合同，以降低关税波动带来的风险并确保供应的连续性。

将产品类型、配方细节、给药策略、品牌定位和分销管道与竞争和营运重点联繫起来的详细細項分析。

关键的市场细分洞察揭示了产品特性、配方设计、给药策略、品牌定位和分销管道结构如何相互作用，从而决定竞争机会和风险。基于产品类型，复方口服避孕药和黄体素单药疗法之间的市场差异导致了处方模式、耐受性特征和目标患者群体特征的差异，进而影响行销、医学教育和处方集。基于配方，双相、单相和三相製剂的差异会影响出血模式、週期管理预期以及医护人员和病患教育所需的讯息。

美洲、欧洲、中东和非洲以及亚太地区的区域战略考量决定了监管重点、通路和製造选择。

区域趋势为不同地理丛集的相关人员带来了不同的策略挑战。在美洲，法律规范、支付方人口结构和远端医疗普及率影响着零售药局、医院采购和线上分销之间的平衡，从而塑造了特定的市场进入模式和报销考量。相较之下，欧洲、中东和非洲地区的监管要求和医疗保健基础设施存在显着差异，因此需要采取适应性强的许可策略、差异化的临床证据包以及定制化的经销伙伴，以反映当地的采购惯例和公共部门的采购週期。

配方创新、供应弹性、策略伙伴关係和生命週期管理的竞争资讯决定了口服避孕药领域的领导地位。

口服避孕药领域的企业竞争格局取决于配方创新、供应链韧性、商业性可行性以及向临床医生和支付方展现差异化价值的能力。关键策略倡议包括投资以患者为中心的讯息传递和用药依从性支援服务，确保关键中间体的长期供应合同，以及优先选择监管途径以加速市场准入。此外，生命週期管理策略，例如分阶段配方变更、包装重新设计和扩大适应症，也被广泛用于提升产品相关性并维持处方医生的支持。

为行业领导者制定可操作的策略重点，以整合证据产生、采购韧性、数位化参与和相关人员，从而确保可持续的市场优势。

产业领导者应采取多管齐下的策略，协调临床证据的取得、供应链的柔软性以及管道特定的商业化，以保持竞争优势。首先，将可靠的真实世界依从性研究和上市后监测整合到产品系列中，可以增强与支付方的议价能力，并有助于制定临床讯息。其次，透过合格的双重采购和选择性近岸外包，实现原料药（API）和成品生产的多元化，可以在保持成本竞争力的同时，降低贸易政策波动和物流中断带来的风险。

严谨的混合方法研究框架，结合相关人员访谈、监管和临床文献整合以及交叉检验的情境分析，为可操作的结论提供了支持。

本分析所依据的研究结合了定性和定量方法，检验趋势、整合不同观点，并为决策者提供切实可行的建议。主要研究包括对临床医生、采购负责人、药房经理和行业高管进行结构化访谈，以获取有关处方行为、筹资策略和分销挑战的第一手资料。次要研究则利用监管文件、临床指引更新、政策公告和公开文献，来分析药物取得和偏好方面的变化。

总结指出，监管变革、供应韧性、配方创新和以患者为中心的交付是该领域未来成功的核心驱动力。

总而言之，口服避孕药市场格局正处于转折点，监管政策的转变、数位化管道的拓展以及供应链趋势的交织，正在重塑产品的研发、交付和使用方式。积极将临床证据的生成与灵活的筹资策略和管道专属的商业化相结合的相关人员，将更有能力满足不断变化的患者需求并降低风险。过渡性政策措施和贸易趋势凸显了灵活采购和建立长期供应商关係的重要性，而製剂差异化和病患支援服务则为企业建立竞争优势提供了清晰的路径。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 口服避孕药市场：依产品类型划分

  • 复方口服避孕药
  • 黄体素单药治疗

第九章 口服避孕药市场：以剂型划分

  • 双相
  • 单相型
  • 三相型

第十章 口服避孕药市场：依剂量划分

  • 高剂量
  • 低剂量

第十一章 口服避孕药市场：依品牌划分

  • 品牌商品
  • 非专利的

第十二章 口服避孕药市场：依通路划分

  • 医院药房
    • 私立医院
    • 公立医院
  • 线上平台
  • 零售药房

第十三章 口服避孕药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 口服避孕药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 口服避孕药市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国：口服避孕药市场

第十七章 中国：口服避孕药市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Bayer AG
  • Cipla Ltd
  • Dr. Reddy's Laboratories Ltd
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Ltd
  • HLL Lifecare Limited
  • Johnson & Johnson Services, Inc.
  • Lupin Pharmaceuticals Inc.
  • Mankind Pharma Ltd
  • Mayne Pharma Group Ltd
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Teva Pharmaceutical Industries Ltd
  • Zydus Lifesciences Ltd
Product Code: MRR-4676B64E6B2E

The Oral Contraceptive Pills Market was valued at USD 19.66 billion in 2025 and is projected to grow to USD 21.05 billion in 2026, with a CAGR of 7.09%, reaching USD 31.77 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.66 billion
Estimated Year [2026] USD 21.05 billion
Forecast Year [2032] USD 31.77 billion
CAGR (%) 7.09%

A succinct orienting overview of the contemporary oral contraceptive pills landscape highlighting clinical, regulatory, and access dynamics shaping stakeholder decisions

Oral contraceptive pills remain a cornerstone of reproductive health strategies globally, and their role in family planning, clinical care, and public health policy continues to evolve. Providers, payers, and manufacturers operate in an environment shaped by shifting regulatory priorities, expanding telehealth provision, and changing patient expectations for safety, convenience, and cost transparency. Consequently, understanding the dynamics that influence prescribing practices, adherence, and accessibility is essential for stakeholders who must balance clinical efficacy with supply chain and commercial realities.

In addition, the social and political context surrounding contraception influences demand patterns, formulary decisions, and public sector procurement strategies. Emerging digital health pathways are reshaping how patients access prescriptions and adhere to recommended regimens, while formulation innovation and lifecycle management of both branded and generic products are redefining competitive dynamics. Therefore, an actionable introduction to this landscape must acknowledge the interplay between clinical guidance, regulatory frameworks, and market channels, and set the stage for deeper analysis that follows in subsequent sections.

How digital health expansion, regulatory rebalancing, and formulation evolution are reshaping access, prescribing behavior, and supplier strategies in the oral contraceptive market

The oral contraceptive market is experiencing transformative shifts that are altering how products are developed, prescribed, distributed, and perceived by users. Advances in digital health have accelerated telemedicine consultations and online pharmacy fulfillment, enabling more rapid access to prescriptions while also introducing new compliance and verification challenges. At the same time, policy movements toward over-the-counter availability in some jurisdictions and expanded pharmacist prescribing authority in others are changing the traditional gatekeepers of access and prompting manufacturers to reconsider packaging, labeling, and patient support services.

Moreover, clinical and formulation trends are prompting differentiated product strategies. Patient-centric formulations and lower-hormone options are gaining attention as providers seek to balance efficacy with tolerability, and there is renewed focus on real-world adherence data to inform guideline updates and payer decisions. Parallel to these clinical shifts are supply-side transformations: contract manufacturing optimization, API sourcing diversification, and vertical integration strategies are being deployed to mitigate disruptions. Finally, increased competition from generic manufacturers and a heightened emphasis on value-based procurement are driving innovation in patient support programs, digital adherence tools, and evidence generation to sustain brand differentiation.

Analyzing how recent United States tariff measures are prompting supply chain realignment, sourcing diversification, and procurement strategy adjustments across the oral contraceptive ecosystem

Recent trade policy measures introduced in the United States have created a cumulative impact across multiple facets of the oral contraceptive supply chain. Increased import tariffs and heightened scrutiny of upstream suppliers can alter the cost calculus for active pharmaceutical ingredient procurement and finished-dose manufacturing, prompting manufacturers to reevaluate sourcing strategies, manufacturing footprints, and inventory policies. As a result, companies are increasingly considering nearshoring, dual-sourcing, and long-term supplier contracts to reduce exposure to tariff volatility and ensure continuity of supply.

At the clinical procurement level, hospitals, clinics, and pharmacies are responding to these shifts by reassessing purchasing agreements and inventory buffers. Transitional effects include renegotiation of tender terms and closer collaboration between procurement and regulatory affairs teams to anticipate customs clearance complexities. In response to potential cost pressures, some manufacturers are enhancing operational efficiency through process improvements and scale consolidation, while others pursue strategic partnerships to secure critical intermediates. Importantly, these structural adjustments are unfolding alongside policy and judicial reviews that may change the long-term tariff landscape, so stakeholders should plan for both immediate operational contingencies and sustained strategic realignments.

In-depth segmentation intelligence linking product type, formulation nuances, dosage strategies, brand positioning, and distribution channels to competitive and operational priorities

Key segmentation insights reveal how product characteristics, formulation design, dosing strategies, brand positioning, and channel structures interact to determine competitive opportunity and risk. Based on Product Type, the market distinctions between combined oral contraceptives and progestin-only pills drive differences in prescribing patterns, tolerability profiles, and target patient cohorts, which in turn influence marketing, medical education, and formulary approaches. Based on Formulation, the differences among biphasic, monophasic, and triphasic designs affect bleeding patterns, cycle control expectations, and the messaging required for clinician and patient education.

Furthermore, based on Dosage Strength, the strategic differentiation between high dose and low dose pills has implications for adverse event profiles, adherence considerations, and patient preference segmentation. Based on Brand, the tension between branded and generic offerings shapes lifecycle management, reimbursement strategies, and investment in patient support or real-world evidence generation. Finally, based on Distribution Channel, the structure that encompasses hospital pharmacy, online platforms, and retail pharmacy-with the hospital pharmacy further studied across private hospital and public hospital environments-determines procurement models, reimbursement flows, inventory practices, and the configuration of patient access programs. Integrating these segmentation lenses enables more precise commercial planning, tailored messaging for clinicians and patients, and alignment of manufacturing volumes with channel-led demand.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory priorities, distribution pathways, and manufacturing choices

Regional dynamics create distinct strategic imperatives for stakeholders operating across different geographic clusters. In the Americas, regulatory frameworks, payer mixes, and telehealth adoption rates influence the balance between retail pharmacy, hospital procurement, and online distribution, driving specific go-to-market models and reimbursement considerations. In contrast, the Europe, Middle East & Africa grouping exhibits wide heterogeneity in regulatory requirements and healthcare infrastructure, which necessitates adaptive licensing strategies, differentiated clinical evidence packages, and tailored distribution partnerships that reflect local procurement norms and public-sector procurement cycles.

Meanwhile, the Asia-Pacific region presents a diverse set of market conditions where rapid digital adoption intersects with variable regulatory timelines and manufacturing capabilities. In many jurisdictions within this region, strong local manufacturing ecosystems and evolving intellectual property enforcement standards affect decisions about local production versus export orientation. Taken together, these regional variations require companies to deploy nuanced market-entry strategies, prioritize regulatory and commercial investments by country or cluster, and synchronize supply chain and distribution models with regional payer and provider behaviors.

Competitive intelligence revealing how formulation innovation, supply resilience, strategic partnerships, and lifecycle management define leadership in the oral contraceptive category

Competitive dynamics among companies active in the oral contraceptive category are defined by a combination of innovation in formulations, supply chain resilience, commercial execution, and the ability to demonstrate differentiated value to clinicians and payers. Leading strategic approaches include investing in patient-centric information and adherence services, securing long-term supply agreements for key intermediates, and prioritizing regulatory pathways that accelerate market access. In addition, lifecycle management tactics such as incremental formulation changes, packaging redesigns, and expanded indications are commonly used to extend product relevance and maintain prescriber loyalty.

Partnerships and alliances, including those with contract manufacturers, digital health platforms, and specialty distributors, are increasingly central to delivering end-to-end solutions that address both clinical adherence and convenience. Meanwhile, companies focusing on generic entry leverage scale manufacturing and cost optimization to compete on price, while larger innovators may emphasize clinical evidence, patient support infrastructure, and brand trust to preserve premium positioning. Across these strategies, firms that align R&D priorities with real-world outcomes and that coordinate effectively across regulatory, supply chain, and commercial functions are better positioned to navigate evolving policy and distribution landscapes.

Actionable strategic priorities for industry leaders to synchronize evidence generation, sourcing resilience, digital engagement, and stakeholder advocacy for sustained market advantage

Industry leaders should adopt a multi-dimensional strategy that harmonizes clinical evidence generation, supply chain flexibility, and channel-specific commercialization to sustain competitive advantage. First, integrating robust real-world adherence studies and post-marketing surveillance into product portfolios will strengthen payer negotiations and inform clinical messaging. Second, diversifying API and finished-dose manufacturing through qualified dual sourcing and selective nearshoring will reduce exposure to trade policy shifts and logistical disruptions while maintaining cost competitiveness.

Moreover, companies should accelerate their digital engagement strategies by embedding telehealth-compatible prescribing support, personalized adherence tools, and seamless e-commerce fulfillment to meet growing patient expectations. Concurrently, active engagement with policymakers, payers, and professional societies will help shape favorable prescribing frameworks and pharmacist scope-of-practice expansions. Finally, leaders should consider targeted investments in brand-differentiating services such as nurse-led counseling, patient education platforms, and value-based contracting pilots to demonstrate outcomes and foster long-term trust with prescribers and patients.

A rigorous mixed-methods research framework combining stakeholder interviews, regulatory and clinical literature synthesis, and cross-validated scenario analysis to underpin actionable conclusions

The research underpinning this analysis relies on a combination of qualitative and quantitative approaches designed to validate trends, triangulate perspectives, and identify practical implications for decision makers. Primary research included structured interviews with clinicians, procurement officers, pharmacy directors, and industry executives to capture firsthand insights on prescribing behaviors, procurement strategies, and distribution challenges. Secondary research drew on regulatory filings, clinical guideline updates, policy announcements, and open-source literature to contextualize shifts in access and formulation preferences.

Data synthesis employed a cross-validation framework that reconciled stakeholder interviews with documented regulatory changes and supply chain developments, while scenario analysis was used to explore the implications of policy and trade variations. Limitations of the methodology include the inherent lag between policy announcements and observable market responses, and the variability of clinical and procurement practices across jurisdictions. Nonetheless, the combined methodological approach provides a robust foundation for strategic recommendations, and the findings were further reviewed by domain experts to ensure relevance and practical applicability.

Concluding synthesis that connects regulatory change, supply resilience, formulation innovation, and patient-centric delivery as the core drivers of future success in the category

In summary, the oral contraceptive landscape is at an inflection point where regulatory shifts, digital access pathways, and supply chain dynamics converge to reshape how products are developed, delivered, and used. Stakeholders who proactively align clinical evidence generation with adaptive sourcing strategies and channel-specific commercialization will be better equipped to meet evolving patient needs and mitigate risk. Transitional policy measures and trade developments underscore the importance of agile procurement and long-term supplier relationships, while formulation differentiation and patient support services offer clear avenues for competitive advantage.

Looking ahead, sustained success will depend on the ability to integrate cross-functional insights into coherent strategies that address both near-term operational challenges and longer-term clinical and market trends. By prioritizing resilience, evidence, and patient-centric delivery models, organizations can navigate uncertainty and harness emerging opportunities to improve access and outcomes for patients who rely on oral contraceptive pills.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Contraceptive Pills Market, by Product Type

  • 8.1. Combined Oral Contraceptives
  • 8.2. Progestin-Only Pills

9. Oral Contraceptive Pills Market, by Formulation

  • 9.1. Biphasic
  • 9.2. Monophasic
  • 9.3. Triphasic

10. Oral Contraceptive Pills Market, by Dosage Strength

  • 10.1. High Dose
  • 10.2. Low Dose

11. Oral Contraceptive Pills Market, by Brand

  • 11.1. Branded
  • 11.2. Generic

12. Oral Contraceptive Pills Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
    • 12.1.1. Private Hospital
    • 12.1.2. Public Hospital
  • 12.2. Online Platforms
  • 12.3. Retail Pharmacy

13. Oral Contraceptive Pills Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Oral Contraceptive Pills Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Oral Contraceptive Pills Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Oral Contraceptive Pills Market

17. China Oral Contraceptive Pills Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Amneal Pharmaceuticals LLC
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Bayer AG
  • 18.9. Cipla Ltd
  • 18.10. Dr. Reddy's Laboratories Ltd
  • 18.11. GlaxoSmithKline plc
  • 18.12. Glenmark Pharmaceuticals Ltd
  • 18.13. HLL Lifecare Limited
  • 18.14. Johnson & Johnson Services, Inc.
  • 18.15. Lupin Pharmaceuticals Inc.
  • 18.16. Mankind Pharma Ltd
  • 18.17. Mayne Pharma Group Ltd
  • 18.18. Merck & Co., Inc.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Sanofi S.A.
  • 18.22. Sun Pharmaceutical Industries Ltd
  • 18.23. Teva Pharmaceutical Industries Ltd
  • 18.24. Zydus Lifesciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PROGESTIN-ONLY PILLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY MONOPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY TRIPHASIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HIGH DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY LOW DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRIVATE HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PUBLIC HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY ONLINE PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 62. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 68. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 69. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 118. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 119. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 136. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 143. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY BRAND, 2018-2032 (USD MILLION)
  • TABLE 163. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA ORAL CONTRACEPTIVE PILLS MARKET SIZE, BY HOSPITAL PHARMACY, 2018-2032 (USD MILLION)